



12 March 2026
EMA/MB/29027/2026 - Adopted
Management Board

Agenda for the 131st meeting of the Management Board Held on 12 March 2026, Virtual (09:00 – 13:30hrs)

Chairperson: Rui Santos Ivo

Item	Title	MB action
1.	Draft agenda	For adoption, EMA/MB/29027/2026*
2.	Declarations of competing interests related to the agenda	Oral report
3.	Minutes from the 130 TH meeting, held on 17-18 December 2025 adopted by written procedure	For information, EMA/MB/389167/2025*
A	Points for automatic adoption/endorsement	
A.1	Revised charters for tasks and responsibilities of the Executive Director as authorising officer and for the Accounting Officer	For information, EMA/MB/360758/2025; For adoption EMA/MB/321163/2025, EMA/MB/336944/2025
A.2	Management Board meeting dates 2026 (rev) and 2027-2028	For information & adoption, EMA/MB/44754/2026*
A.3	Revision of policy 0082 Union Product Database (UPD) Access Policy and Joint Controllership	For information, EMA/MB/24124/2026; For adoption, EMA/354254/2025*; For endorsement, EMA/366104/2021*
A.4	Rules for reimbursement of expenses for delegates attending meetings	For information, EMA/MB/40815/2026; For adoption, EMA/MB/279597/2018*
A.5	MB Decision on empowering ED to request derogation from Commission decision on geographical balance of staff	For information, EMA/MB/24149/2026; For adoption, EMA/MB/389779/2025; For information, Ares (2025)9975581



Item	Title	MB action
B	Points for discussion	
B.1	Highlights of the Executive Director	Oral report
B.2	Report from the European Commission	Oral report
B.3	Update on the preparations for implementation of the new EU pharmaceutical legislation, once adopted	Oral report
B.4	EMA Annual Report 2025	For information, EMA/MB/41617/2026; For adoption, EMA/17207/2026*
B.5	2025 EMA Annual Report on Independence	For information, EMA/MB/36377/2026; For adoption, EMA/8063/2026*
B.6	Draft ePI roadmap	For information, EMA/MB/33111/2026
B.7	2024-2025 biennial report on stakeholder engagement	For information, EMA/149424/2025*
B.8	Update on cybersecurity management at EMA	Oral report
B.9	Clinical trials in the EU: <ul style="list-style-type: none"> • Policy and legislative update (European Commission) • CTIS update and ACT EU highlights • Joint Controllership Arrangement (JCA) for CTIS 	Oral report; For information, EMA/MB/29027/2026, EMA/42932/2026; For information, EMA/MB/41030/2026; For endorsement, EMA/541334/2021
B.10	Update from Network Data Steering Group (NDSG)	For information, EMA/MB/49487/2026, EMA/51241/2026*
B.11	Status update on African Medicines Agency (AMA)	Oral report
C	Points for information only**	
C.1	Outcome of written procedures finalised during the period from 5 December 2025 to 3 March 2026	For information, EMA/MB/316806/2025*
C.2	2025 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission Reporting period: 1 January to 31 December 2025	For information, EMA/MB/36132/2025, EMA/371010/2025*
C.3	Twenty first, six-monthly report on <i>ex ante</i> and retroactive evaluation of projects for the period 1 July to 31 December 2025	For information, EMA/MB/25406/2026, EMA/17537/2026
C.4	Network Portfolio Report	For information, EMA/MB/50799/2026, EMA/50755/2026

Item	Title	MB action
C.5	Summary of transfers of appropriations in budget 2025	For information, EMA/MB/29027/2026
C.6	Draft Annual Activity Report (AAR) 2025	For information, EMA/MB/50522/2026, EMA/43071/2026
C.7	EMA working document on buildings	For information, EMA/MB/29770/2026, EMA/29769/2026
C.8	Report on external experts remunerated under Article 93 of the EMA Financial Regulation – Calendar year 2025	For information, EMA/MB/29027/2026, EMA/40110/2026
C.9	Management Board Audit and Risks. Group (MBARG) – Minutes of 4 February meeting	For information, EMA/MB/29027/2026

* Documents marked with a star * are intended for publication on the external website.

** Documents in *Additional documents for information* section are not intended for discussion unless specifically requested.